- Home
- AXGN
AXGN
Axogen Inc.
as 05-17-2024 4:00pm EST
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | ALACHUA |
| Market Cap: | 251.3M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 334.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.45 - $10.83 | Next Earning Date: | 05-02-2024 |
| Revenue: | $163,726,000 | Revenue Growth: | 13.51% |
| Revenue Growth (this year): | 15.15% | Revenue Growth (next year): | 12.80% |
Share on Social Networks:
Stock Insider Trading Activity of Axogen Inc. (AXGN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Donovan Michael Patrick | AXGN | VP Operations | Mar 16 '24 | Sell | $7.68 | 4,596 | $35,297.28 | 54,250 | SEC Form 4 |
| Donovan Michael Patrick | AXGN | VP Operations | Mar 16 '24 | Sell | $7.68 | 721 | $5,537.28 | 40,221 | SEC Form 4 |
| Donovan Michael Patrick | AXGN | VP Operations | Mar 16 '24 | Sell | $7.68 | 716 | $5,498.88 | 37,992 | SEC Form 4 |
| Zaderej Karen L. | AXGN | CEO | Mar 16 '24 | Sell | $7.68 | 33,028 | $253,655.04 | 1,124,565 | SEC Form 4 |
| Zaderej Karen L. | AXGN | CEO | Mar 16 '24 | Sell | $7.68 | 3,086 | $23,700.48 | 1,133,979 | SEC Form 4 |
| Zaderej Karen L. | AXGN | CEO | Mar 16 '24 | Sell | $7.68 | 3,166 | $24,314.88 | 1,143,788 | SEC Form 4 |
| DeVinney Erick Wayne | AXGN | Chief Innovation Officer | Mar 16 '24 | Sell | $7.68 | 716 | $5,498.88 | 165,661 | SEC Form 4 |
| DeVinney Erick Wayne | AXGN | Chief Innovation Officer | Mar 16 '24 | Sell | $7.68 | 721 | $5,537.28 | 167,890 | SEC Form 4 |
| DeVinney Erick Wayne | AXGN | Chief Innovation Officer | Mar 16 '24 | Sell | $7.68 | 3,141 | $24,122.88 | 177,474 | SEC Form 4 |
| Scopelianos Angelo | AXGN | Chief R&D Officer | Mar 16 '24 | Sell | $7.68 | 5,251 | $40,327.68 | 52,999 | SEC Form 4 |
| Scopelianos Angelo | AXGN | Chief R&D Officer | Mar 16 '24 | Sell | $7.68 | 1,020 | $7,833.60 | 56,104 | SEC Form 4 |
| Scopelianos Angelo | AXGN | Chief R&D Officer | Mar 16 '24 | Sell | $7.68 | 610 | $4,684.80 | 57,994 | SEC Form 4 |
| Donovan Michael Patrick | AXGN | VP Operations | Mar 7 '24 | Sell | $8.81 | 36,310 | $319,891.10 | 35,708 | SEC Form 4 |
| Freitag Gregory Gene | AXGN | Director | Mar 7 '24 | Sell | $9.00 | 25,000 | $225,000.00 | 271,594 | SEC Form 4 |
| MARIANI PETER J | AXGN | EVP & Chief Financial Officer | Dec 11 '23 | Sell | $7.52 | 1,410 | $10,603.20 | 74,693 | SEC Form 4 |
| MARIANI PETER J | AXGN | EVP & Chief Financial Officer | Dec 11 '23 | Sell | $7.51 | 3,120 | $23,431.20 | 71,573 | SEC Form 4 |
| MARIANI PETER J | AXGN | EVP & Chief Financial Officer | Dec 11 '23 | Sell | $7.50 | 7,970 | $59,775.00 | 63,603 | SEC Form 4 |
Latest Axogen Inc. News
AXGN Breaking Stock News: Dive into AXGN Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
MT Newswires
3 days ago
AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft
GlobeNewswire
4 days ago
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
GlobeNewswire
6 days ago
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
Insider Monkey
13 days ago
AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript
Simply Wall St.
17 days ago
AxoGen First Quarter 2024 Earnings: Misses Expectations
GuruFocus.com
17 days ago
Axogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges
Zacks
18 days ago